UCL ADVANCED CENTRE FOR Biochemical Engineering In this issue EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies Developments Industrial Doctoral Training Centre Success iGEM Gold MBI® Programme Developments ISSUE TEN | APRIL 2013 0376_2013_UCL_BPM10_proof3.indd 1 14/05/2013 12:37 Contents Departmental News Editorial 3 EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies Latest Developments 7 Our Undergraduate Crooks Society 11 VISION News 12 IDTC News: iGEM Gold 14 Industrial Training Open Day 16 Industrial Biotechnology & Biorefining MBI® CPI Success 17 Single Use MBI® 18 MBI® Course Dates 20 Foreword by Professor Nigel Titchener-Hooker I am often asked what is the secret to the success of UCL Biochemical Engineering. There is no secret other than the staff, the students and the support of those we work with! This issue of Bioprocessing Matters highlights just some of the ways in which these three elements come together to make the department what it is. As ever the articles demonstrate the wide variety of activities we are involved with and it is always exciting to see how these have often grown from really small ideas into major opportunities. We have hugely energetic student societies. Our undergraduates for example, have created a truly impressive programme of careers events bringing in high level speakers from a diversity of companies. This kind of initiative not only helps to forge relationships but cements in people’s minds the unique qualities of our students. Our staff are constantly innovating and in this issue you will read about read about our BBSRC Sparking Impact Award and our new EPSRC and ERA-Net awards in Industrial Biotechnology. Such initiatives are key to the success of the department as we move forward and into a period in which it shall be critical to diversify the sources of funding we use to grow our activities. The industry we work with is, I think, unusually cohesive. This is important for a relatively new academic discipline and here at UCL we enjoy and benefit from a totally unparalleled level of sector support. This allows us to engage in strategic initiatives on both the research and training fronts. Great examples are highlighted in this issue of BPM including our latest EPSRC Centre where the user support is fundamental and also a report on our Industrial Training Open Day. Thank you for your support. I hope you find the contents of this issue interesting, and as ever look forward to receiving feedback. Prof. Nigel Titchener-Hooker Head of Department and Director of the Advanced Centre for Biochemical Engineering 2 0376_2013_UCL_BPM10_proof3.indd 2 14/05/2013 12:37 Prof Nigel Titchener-Hooker wins Donald Medal Our Head of Department, Professor Nigel Titchener-Hooker has been awarded the prestigious Donald Medal by the Council of the Institution of Chemical Engineers. The medal, awarded for individual contribution to biochemical engineering, is named after a former UCL Ramsay Professor. Professor Mike Hoare wins Alan S. Michaels Award Congratulations to Professor Mike Hoare on being the 2013 Alan S. Michaels awardee. This is a prestigious award presented by the Division of Biochemical Technology (BIOT) of the American Chemical Society (ACS). The award recognises his many contributions to the field, but in particular his seminal contributions to downstream processing including pioneering studies of ultra scale-down and advances of industrial ® relevance to key unit operations. CosmoClear – YES A team of aspiring biotechnology entrepreneurs from UCL Biochemical Engineering have scooped a prize at the Biotechnology Young Entrepreneurs Scheme (YES) 2012 in London. The team behind the CosmoClear company had the idea of patenting a specific combination of probiotic bacteria able to control oily skin. ProBaClearTM provides a unique alternative to chemical products currently available which can have negative effects on the condition of the skin. This won them the ‘Best plant and microbial business plan’ category sponsored by Syngenta. Minister for Universities and Science David Willetts said, “The participants in this competition have shown that there is a bright future ahead for biological science. This is one of the most vibrant and increasingly important sectors of the UK. They are developing the skills needed to translate world class research into wider economic and social benefits.” 3 0376_2013_UCL_BPM10_proof3.indd 3 DEPARTMENTAL news Departmental News John Thwaites, Giulia Detela, Yvonne Pang, Leanne Partington, and Thomas Iwan. 14/05/2013 12:37 DEPARTMENTAL news Dr Karen Smith elected FSB and AFIChemE Dr Karen Smith has been elected a Fellow of the Society of Biology and as Associate Fellow of the Institution of Chemical Engineers (IChemE). Prof John Ward joins academic staff Prof John Ward studied Biochemistry at the University of Bristol and graduated in 1975. He moved departments and joined the Department of Bacteriology to carry out research for his PhD on antibiotic resistance plasmids and transposable elements using the newly discovered restriction enzymes. After gaining his doctorate in 1981 he moved to UMIST in Manchester to a postdoctoral position on Pseudomonas catabolic plasmids. In 1983 he came to University College and started the MSc in Applied Molecular Biology and Biotechnology and in 2011 started the MRes in Synthetic Biology. John will provide fundamental bioscience support for our activities in Synthetic Biology across all aspects of departmental activity. Dr Sofia Simaria joins academic staff Dr Sofia Simaria has been appointed as Lecturer in Bioprocess Systems Engineering in the Department of Biochemical Engineering in November 2012. She has a PhD in Industrial Engineering and has joined UCL in 2008 to work as postdoctoral research associate in the area of Decisional Tools. Her research focuses on the development of computer-based decisionsupport models that capture the process-business interface of biopharmaceutical and cell therapy manufacture. Sofia coordinates the new MEng/MSc course module Bioprocess Systems Engineering, designed to provide students with skills in advanced modelling, optimisation and statistical techniques such that they are adequately equipped to address problems related to evaluating the cost-effectiveness and robustness of alternative bioprocess design strategies. 4 0376_2013_UCL_BPM10_proof3.indd 4 14/05/2013 12:37 In the previous issue of BPM we reported on new directions that UCL biocatalysis research is taking with the award of a BBSRC grant to work on aspects of biorefinery processing for UK-based bioethanol production. In the last six months this has been followed up with a series of major grant wins many of them to establish new engineering and synthetic biology tools to speed biocatalytic process development. This led to a visit on 7th March by the Minister for Science, David Willetts, who toured ACBE pilot plant facilities and met with representatives from the UCL spin-out company Synthace. First there was the award of a £1.92M EPSRC grant to Prof Gary Lye, Prof John Ward and Dr Paul Dalby (UCL Biochemical Engineering) and Prof Helen Hailes and Dr Tom Sheppard (UCL Chemistry) to work on ‘Bioderived feedstocks for sustainable, UK-based manufacture of chemicals and pharmaceutical intermediates’. This is in collaboration with colleagues at Imperial College and the University of Bath and involves 11 company partners including British Sugar and GlaxoSmithKline. This was followed by EU funding success from the ERA-NET programme in Industrial Biotechnology. Dr Nicolas Szita and Dr Frank Baganz (UCL Biochemical Engineering), together with collaborators from four other European universities, including the Technical University of Denmark, won a €1.8M grant on ‘Microtools for downstream processing’ to develop a microscale downstream processing toolbox for screening and development of biocatalytic processes. Dr Martina Micheletti and Prof Gary Lye (UCL Biochemical Engineering) were also part of a successful £2.3M ERA-IB grant to work on ‘Integrative approach to promote hydroxylations with novel P450 enzymes for industrial processes’. This grant is led by the German company c-LEcta and involves six academic and industrial partners in Germany and Belgium. Most recently Dr Frank Baganz and Dr Chris Grant (UCL Biochemical Engineering) were involved in a £430k Technology Strategy Board grant to work on ‘rapid engineering of cellular factories’ in collaboration with the University of Manchester. This is led by the spin-out company Synthace and aims to advance the industrial application of synthetic biology. For further information on UCL Industrial Biotechnology research please contact Prof Gary Lye: Tel: +44 (0)20 7679 7942 or Email: Lye ay g.lye@ucl.a.uk DEPARTMENTAL news Ministerial Visit Following Further Industrial Biotechnology Funding Success Minister for Science, David Willetts with Dr Chris Grant 5 0376_2013_UCL_BPM10_proof3.indd 5 14/05/2013 12:37 DEPARTMENTAL news Our students make a difference –volunteering in Sri Lanka For 5 weeks, UCL Biochemical Engineering student Stephan Joseph ran activities at children’s homes and special needs centres, and taught English to unemployed youths aged 18-25 in Sri Lanka on a project run by SL Volunteers. Project Manager, Lucy Nightingale said “We value students that study Biochemical Engineering, as they have the skill set that we are looking for. Having Stephan being so positive, hardworking and committed to the projects has meant that our organisation has improved a lot over the summer.” For further information see www.slvolunteers.com MBI® and VISION Twitter pages We have recently launched Twitter pages for both MBI® and VISION and hope that you will ‘follow’ us at: @UCL_MBI and @UCL_VISION to hear all our latest thoughts on the post-experience training front and interact with us. Sparking Impact Award We are delighted to announce that we have won a BBSRC Sparking Impact Award. This Award of £100k will enable us to fund the kind of highly varied and small scale knowledge exchange and commercialisation (KEC) activities required at the earliest stages of progressing research outcomes towards impact. The Principle Investigator for this award is Prof John Ward and the administration of the funding will be undertaken by the Office of the ViceProvost (Enterprise). Strategic priorities are to enhance and expand the use of Biotechnology advances by UK companies. Examples of these advances include new enzymes in industrial processes and novel routes to identify these, strategies to improve enzymes or bioprocesses to generate bio-derived compounds or materials. Also new biologically active compounds. We would also want to carry out the preliminary market research to develop ideas and build the means whereby researchers could develop and start their own companies based on their BBSRC funded research. 6 0376_2013_UCL_BPM10_proof3.indd 6 14/05/2013 12:37 Flagship research The centre funded initially for five years by the Engineering and Physical Sciences Research Council is now in its second year. A team of eight PDRAs are engaged on two linked flagship projects which account for 60% of the Centre budget. The first flagship project led by Paul Dalby seeks to establish a framework for rapid determination of manufacturability of bulk product and final dosage form. This research flagship aims to create indices that rank macromolecular products in terms of their manufacturability as a) the bulk active drug substance and b) the final drug product in a patient dosage form. These indices will act as early predictors of bioprocess performance. Such ranking would allow decision makers to weigh up manufacturability and product dosage form options along with their knowledge of potential clinical efficacy, to select the most promising proteins from panels of candidates, and eliminate those most likely to fail due to difficulties in bulk product manufacture and final formulation. The second flagship led by Dr Suzy Farid is developing decision-support tools for biomanufacturing lifecycle analysis under uncertainly. This flagship research aims to: • Generate a biomanufacturing lifecycle evaluation tool to enable the costs of manufacture, as well as the costs of treatment, to be predicted as a consequence of the decisions made during manufacture and product design. • Establish a decision-support optimisation tool to locate the most costeffective combination of process parameters, process sequence, formulation method and facility design whilst assessing manufacturing robustness under uncertainty. • To develop advanced multivariate analysis tools to predict the degree of facility fit and root causes of product loss when optimal processes are transferred into existing facilities. EPSRC Centre Developments EPSRC Centre For Innovative Manufacturing in Emergent Macromolecular Therapies Developments 7 0376_2013_UCL_BPM10_proof3.indd 7 14/05/2013 12:37 EPSRC Centre Developments CANDIDATE MOLECULES F1.1 F1.2 Ranking of protein properties Cause-and-effect from USD data Led by Paul Dalby, UCL BE Steve Brocchini, UCL SoP Led by Nigel Titchener-Hooker, UCL BE Lazaros Papageorgiou, UCL CE CANDIDATE MOLECULE F2.1 F2.2 F2.3 Lifecycle costs Lifecycle optimization Facility fit Led by Suzanne Farid, UCL BE Steve Morris, UCL/UCLH Led by Suzanne Farid, UCL BE Lazaros Papageorgiou, UCL CE Led by Nina Thornhill, Imperial CE Suzanne Farid, UCL BE National Centre for Doctoral Training in Macromolecular Therapies In 2012 funding was won for a Centre for Doctoral Training (CDT) linked to the EPSRC Centre. The CDT is being delivered in partnership with other leading research universities and is helping to build an enhanced network of research collaborations based on the EPSRC Centre. Five doctoral projects started in 2012 and a further five are expected to start in autumn 2013. Platform Activities The Flagship projects are complemented by a programme of Platform events and activities that are intended to establish the Centre as a national resource and to broaden its research base by growing the number of collaborations. 8 0376_2013_UCL_BPM10_proof3.indd 8 14/05/2013 12:37 Research progress over the first year was reported at the first annual research meeting held on 18th September 2012 with a focus on the launch of the Responsive Bioprocessing Facility. The event was titled Biomanufacturing: New Challenges & New Paradigms and was attended by over a 100 delegates. Three keynote talks were given by industry leaders in single-use bioprocessing as well as presentations providing an overview of the Centre and Departmental activity in this area and the meeting. Programme for Biomanufacturing: New Challenges & New Paradigms EPSRC Centre Flagship Research Nigel Titchener-Hooker/ Paul Dalby/ Suzanne Farid, UCL keynote: Robotic Platform for Rapid Delivery Markus Zamponi, Bayer keynote: Implementation of Integrated Kevin Brower, Genzyme keynote: Implementation of Disposable Sandrine Dessoy, GSK Responsive Bioprocessing facility (RBF) – Research & Training Agenda Gary Lye, UCL Engineering Characterisation of Single-use Bioreactors for Improved Process Predictability Martina Micheletti, UCL Evaluating the Cost-effectiveness of Single-use Technologies for Cell Therapies Suzanne Farid, UCL of Personalised Vaccines Continuous Bioprocessing for Biologics Bioreactors for Viral Vaccines Process Development EPSRC Centre Developments 1st Annual Research Meeting Innovation workshop at the 9th Annual bioProcessUK Conference in Bristol 29th November 2012 BioProcess UK invited Dr Suzy Farid to organise a 90 minute workshop at its annual conference to explore the issues and drivers for innovation in biopharmaceutical manufacturing. The object of the workshop was to access the experience of practitioners in the UK to understand better the challenges and opportunities for innovation in this sector. The workshop explored three themes: • Is Innovation still required if so where? • How do you balance risk versus benefits when implementing new technologies?, and • Is new technology R&D investment directed towards the most pressing issues? This session received very positive feedback from the delegates and the proceedings are being summarised for publication to help inform the wider debate about innovation in biopharmaceutical manufacturing. 9 0376_2013_UCL_BPM10_proof3.indd 9 14/05/2013 12:37 EPSRC Centre Developments Feasibility Studies A call for proposals for research feasibility studies aligned to the Centre programme was issued via EPSRC website in early November 2012. We received 13 outline proposals requesting funding of £230k in total. Five of these, worth £84k funding have been selected for funding and are expected to start late March. A sixth project will be taken forward as a CDT studentship. Selected feasibility studies from November 2012 call Presenter Institution Topic Mire Zloh University of Hertfordshire Freeze drying, molecular dynamics simulation Stephanie Allen University of Nottingham Biopysics; AFM; bioformulation; bioprocessing Alexander ‘Sasha’ Golovanov University of Manchester NMR biopharmaceutical proteins aggregation Svetlana Ignatova Brunel University Analytical aqueous phase partitioning (AAPP) for the biophysical characterisation of protein isoforms/ adenovirus, liquid-liquid technology, scalability Dan Bracewell UCL Polymeric nanofibre adsorbents Vaccine Workshop 13th February 2013 In collaborations with the Knowledge Transfer Networks for Biosciences and for Healthcare and Medtech, the EPSRC Centre organised a workshop on Vaccines “Getting early stage products into development and manufactureRapid response scale up to emerging disease threats”. Over 75 delegates from both academic and industrial groups attended. The strong feedback from those attending suggests that there is a strong interest in further meetings and community building activities in this area. EPSRC Centre Bioprocess Briefings These briefings are an important part of the wider outreach activity for the EPSRC Centre and are open to anybody from the bioprocessing community. Bioprocess briefings delivered since October: • 19th November 2012: ‘Protein Aggregation’. Dr Grant Grieve, Fujifilm Diosynth Biotechnologies • 31st January 2013: ‘MALDI-Mass Spectrometry Imaging in Drug Discovery’ Dr Peter Marshall, GSK • 7th February 2013: ‘Advances in the manipulation of bioparticles using electric fields within microsystems’ Dr Henry Fatoyinbo, University of Surrey. For further information about the EPSRC Centre please contact Prof Nigel Titchener-Hooker at nigelth@ucl.ac.uk 10 0376_2013_UCL_BPM10_proof3.indd 10 14/05/2013 12:37 The Crooks Society Our undergraduate Crooks Society has had a busy year organising career talks across the biopharma, energy and food and drink sectors from: Aggio, Eli Lilly, Ensus, GSK, IBM, Kraft, Pall, P&G, Shell and Tate & Lyle. Following the ‘Work hard – play hard ’ adage they also hosted a range of highly successful networking and social events including bowling, iceskating, a boat party, IChemE pub quiz, summer BBQ and Christmas Ball. A particular highlight was a trip to Oxford to attend the IChemE Thames Valley Biotechnology showcase, networking with participating companies (Pall, Lonza, Patheon, Oxford Biomedica, etc.). One student even managing to secure an internship from Lonza! Despite all this activity, they still had the energy to arrange a number of sporting fixtures such as netball, football and participating in the Frank Morton Sports Day. Go Crooks! 11 0376_2013_UCL_BPM10_proof3.indd 11 14/05/2013 12:37 VISION “Connectivity is our strength” The VISION programme aims to be the nexus for the leaders of the biological sciences industry to hear and debate the latest technological and business developments in the sector. Recent VISION Briefings: • 5/3/2013: VISION-PALL DAY – Discover Your Future…Today! • 26/2/2013: A perspective on the future of medical provision. Ray Hill, visiting Professor of Pharmacology, Dept of Medicine, Imperial College London • 19/2/2013: Stem cell therapy clinical trials – the rigours ofEU and UK regulation. Dr Mark Richardson PhD FTOPRA • 29/1/2013: R&D costs of a new medicine: what are the key drivers?. Dr Jorge Mestre-Ferrandiz, Director of Consulting, Office of Health Economics • 6/12/2012: Technology challenges to meet the expanding vaccine boundaries. Prof Barry Buckland, CEO, BioLogicB • 27/11/2012: Future of downstream processing and the role of continuous chromatography. Dr Marc Bisschops, Chief Scientific Officer, Tarpon Biosystems 12 0376_2013_UCL_BPM10_proof3.indd 12 14/05/2013 12:37 Forthcoming VISION Events Briefing: 25th April 2013 ‘The Role of the Catapult Centres (and the Centre for Process Innovation in Particular) in Delivering Innovation in Biotechnology’ Speaker: Dr Graham Hillier, Director of Strategy and Technology, CPI and the High Value Manufacturing Catapult. Venue: Executive Front Suite, Roberts Building, Torrington Place, London, WC1E 7JE. Cost: £50. Time: 17:00 Core Course: 22-24th May 2013 Our next VISION core offering will be held on the 22-24th May 2013 and is our fourth Senior Leadership Course designed to help real people shape companies in the sector. Over a period of three days, sector specific talks from thought leaders, facilitated case studies and interactive problem-solving exercises will enable you to enhance your capabilities. Highlights include: • Pathfinder: Executive Networking Workshop • Theme 1: Changing Life Cycle and Alternative Business Models • Theme 2: Leadership and Innovation • Theme 3: Internal and External Risks and Supply Chain A range of expert speakers drawn from Europe and the US will include: • Professor Steve Arlington, Partner, Head of Life Sciences Practice, PriceWaterhouseCoopers • Dr Gunter Jagschies, Senior Director Strategic Customer Relations Leader, GE • Dr Michelle Scott, Partner, Unicorn Biologics • Dr Andrew Ramelmeier, Vice President of Manufacturing &Facilities, BioMarin • Dr. Rahul Singhvi, President, Managing Partner Axella, LLC • Prof Barry Buckland , CEO of BiologicB • Dr Alain Pralong, Vice President New Production Introduction and Life Cycle, GSK • Vicki Salmon, Partner, IP Asset LLP After Dinner Talk: • Charles Cooney, Professor of Chemical and Biochemical Engineering and Faculty Director of the Deshpande Center, M.I.T. For further information about either please contact Dr Karen Smith at karen. smith@ucl.ac.uk or Prof Eli Keshavarz-Moore at e.keshavarz-moore@ucl.ac.uk or see our dedicated VISION website www.vision-ucl.co.uk 13 0376_2013_UCL_BPM10_proof3.indd 13 14/05/2013 12:37 Industrial Doctoral Training Centre IDTC NEWS Industrial Doctoral Training Centre (IDTC) Developments IDTC Success at iGEM 2012 Two Engineering Doctorate (EngD) students from the UCL IDTC in Bioprocess Engineering Leadership enjoyed outstanding success in 2012 as members of the UCL ‘Plastic Republic’ team competing in the International Genetically Engineered Machines (iGEM) Synthetic Biology competition. The team’s hard work was recognised by their being awarded a Gold Medal at the ultra-competitive European iGEM Finals event in Amsterdam and being selected to progress to the iGEM World Championship Finals in the USA. At the Finals UCL’s Plastic Republic were ranked as the top UK iGEM team and also received the Best Presentation award. Alexander Templar (EngD in partnership with BJS Biotechnologies Ltd) and James Rutley (EngD in partnership with Synthace) used cutting edge bioprocess and synthetic biology techniques to demonstrate the capabilities of a marine bacterium designed to bio-remediate waste plastic from the Earth’s oceans. iGEM is an annual student synthetic biology competition started at the Massachusetts Institute of Technology (MIT) in 2004. Since its inception iGEM has grown from five participating US universities into an international competition spanning 193 universities worldwide. Regional finals are held in Europe, Asia, South America and the east and west coasts of North America, with the best teams from each region advancing to the World Championship Finals hosted at MIT. 14 0376_2013_UCL_BPM10_proof3.indd 14 14/05/2013 12:37 Industrial Doctoral Training Centre IDTC NEWS UCL Biochemical Engineering has hosted UCL ‘UCL’s Plastic iGEM teams since 2009, harnessing its unique position Republic were as a centre of excellence in whole bioprocessing ranked as the (from upstream cell engineering to downstream unit top UK iGEM operations) to provide cutting-edge bioscience and team and rigorous engineering training. James Rutley led the also received Plastic Republic’s efforts to mimic the shear forces the Best present in the deep ocean using a shear device to test Presentation the ability of marine bacteria to bind and aggregate award’ microplastic particles. As part of his ongoing EngD research with the BJS Biotechnologies xxpress® UltraFast PCR device, Alex Templar helped the team build the new ‘BioBrick’ DNA constructs used to modify the marine bacterium. For the first time in the history of the competition, the UCL iGEM team also collaborated with members of the public in designing and assembling BioBricks. Translating skills gained at the IDTC, James, Alex and their Plastic Republic team mates worked with members of the public at the London Hackspace facilities in the Tech City zone of East London to devise modifications to the marine bacterium Oceanobulbus indoliflex. Construction of the first ever ‘Public BioBrick’ then began on site at UCL with iGEM students and Hackspace members working side by side. The hard work paid off and IDTC researchers continue to be an important part of UCL iGEM activities for 2013. 15 0376_2013_UCL_BPM10_proof3.indd 15 14/05/2013 12:37 Industrial Training Open Day Our Industrial Training Open Day was held on the 7th of March 2013 and 14 senior industrialists representing the following companies attended: Astex, Biopharm Services, BP, BPL, Cambridge Bioprocess Management Ltd, Cantab, eXmoor, GSK, HPA, Ipsen, ImmBio, Pall, Tillingbourne Consultancy and UCB. During the Industrial Training Advisory Board (ITAB) and the Industrial Doctoral Training Centre Board (IDTC) meetings in the morning they heard about our plans to launch a new MBI® module in Single-use Technologies in 2014. Another highlight was hearing of the proposed Chamges to the Mammalion Cell Processes MBI® module. Prof Gary Lye also spoke about the success of the new MBI® - CPI (Centre for Process Innovation) Industrial Biotechnology and Biorefining module held at CPI in Wilton in October 2012. He then went on to provide an update on IDTC recruitment and company participation, achievements of first graduating cohort and plans for forthcoming EPSRC rebidding. The session was chaired by Professor John Birch (formerly Lonza Biopharmaceuticals Chief Scientific Officer). In the afternoon second and third year undergraduates relished the opportunity to meet senior industry leaders and ask them questions about various sectors, careers and internship opportunities in a relaxed afternoon session “A Cuppa with ITAB”. Over 20 students pitched their questions to the industrialists who were delighted to provide insight into life at the cutting-edge. A Poster and Networking session was held during lunch and BPL once again sponsored the £200 prize for the best poster which this year went to Edward Close for his poster entitled ‘A model based approach to an adaptive design space in chromatography’. Roberts Prizes interviews also took place during the day (the Scholarships are awarded for first year Biochemical Engineering undergraduates at UCL who show exceptional promise and commitment to the discipline). The following students were presented awards at the Departmental Team Briefing by Helen Mason of BP: • Andreas Paxinos • Cathy Pang • Emily Yuan • Nadzirah Norazman • Thomas van Tergouw For further information about the Industrial Training Open Day or ITAB please contact Dr Karen Smith at karen.smith@ucl.ac.uk 16 0376_2013_UCL_BPM10_proof3.indd 16 14/05/2013 12:37 Industrial Biotechnology & Biorefining MBI® – CPI Success The MBI® module “Industrial Biotechnology and Biorefining: From Synthetic Biology to Process Engineering” was fully revamped this year as a collaboration with the Centre for process innovation (CPI) at Wilton. Delegates, who came from organisations such as AB Sugar, Crucell , GSK, Shell Global Solutions and NEPIC, were given a mix of background fundamentals, emerging technologies and real industrial case histories by UCL staff, while CPI provided access to their large-scale facilities and an overview of the practical considerations for scaling up biocatalytic reactions. This new collaborative arrangement will be further enhanced in the coming year with a practical session at CPI to give delegates a hands-on experience with biocatalytic scale-up. For further information contact Dr Paul Dalby at p.dalby@ucl.ac.uk Tim Hughes Award In recognition of the invaluable contribution Tim Hughes has made to the Quality by Design for Effective Bioprocess Characterisation MBI® module over a 17 year period, we were delighted to present him with a silver salver to mark the occasion on the 27th February 2013. Tim is now based in Australia and so he will contribute to the module on a less comprehensive basis going forward. Richard Francis has joined the team seamlessly to assist Dr Suzy Farid in delivering the module. Tim is pictured receiving his award from Nigel TitchenerHooker, Head of Department. The QbD module is an excellent route by which to obtain expert guidance on choosing on how best to integrate QbD, DoE and PAT into lifecycle approach to process characterisation. For further information, please contact Dr Suzy Farid at s.farid@ucl.ac.uk 17 0376_2013_UCL_BPM10_proof3.indd 17 14/05/2013 12:37 Single Use MBI® The MBI® Training Programme is run by the Department and comprises a series of UCL accredited short courses in bioprocessing, designed specifically for industrialists. They can be taken as standalone modules or can be combined for certificate, diploma or Masters qualifications. To date 1,200 modules have been taught to over 800 international delegates, and more than 200 companies have participated. For further information please email Dr Karen Smith at karen.smith@ucl.ac.uk or telephone 0207 679 4411. www.ucl.ac.uk/biochemeng/ industry/mbi/courses Building on the Department’s significant investment in single-use technology and the recent launch of the UCL Responsive Bioprocessing Facility (RBF) in September 2012, the Department is now announcing the development of a new MBI® module based on single-use technology (SUT) for rapid manufacturing. This represents an exciting new focus that is based on current research activities in studies such as mixing in different bioreactor systems, evaluation of the impact of aeration on antibody production and novel culture systems for rapid optimisation of phototrophic microalgae cultivation. The module will run from the 2013-14 academic year with course dates set for 9-11 June 2014 and will complement our current course set by offering fundamental, applied and practical knowledge on SUT-based bioprocess operations. The aim of the course is to establish and deliver new training material specific to single-use technology encompassing different process steps, scales of operation and cell/product systems. The whole process will be considered and tools useful for the evaluation and adoption of SUT for a range of process steps will be provided. Numerical case studies on process fundamentals will provide confidence in scale translation and in the use of SUT as scale-down models while discussion will focus on the different stages of the development pathway, from initial discovery and screening to manufacturing. The course material will be revised yearly depending on market needs and industrial requirements and in the first few runs aims to look at critical issues such as standardization, supply chain management, risk of failure, validation and environmental impact of this technology. While SUT can be considered relatively well established for monoclonal antibody production, the course will also consider SUT evaluation for adherent cells systems and microbial fermentation. For further information, please contact Dr Martina Micheletti at m.micheletti@ucl.ac.uk A group of attendees visiting the RBF Suite during the 18th September 2012 launch event 18 0376_2013_UCL_BPM10_proof3.indd 18 14/05/2013 12:37 MBI® Module: Bioprocess Design and Economic Evaluation (24-27th June 2013) Focussing on how to specify the process and how to determine its economic feasibility This module focuses on how to specify a complex bioprocess and determine its economic feasibility. It will: • Specify a major item of process equipment. • Interpret engineering drawings used in equipment procurement. • Perform economic analyses of the process and determine sensitivities to process changes. • Achieve value for money in complex engineering projects. • Recommend a process that is technically feasible and economically viable. • Determine the types of data needed to specify unit operations and processes. • Develop process flowsheets and mass balances. Who should attend? This course is designed for engineers, chemists, biologists, biochemists and biotechnologists who are interested in process design for the manufacture of biological products. Each concept and topic covered will be explained for the beginner - an example case study is followed through the bioprocess design procedure to allow an economic appraisal of the design to be performed. This learning is carried forward to the following “Bioprocess Facility Design” course which examines the next stage of a bioprocess design. Typically delegates are: R&D scientists, engineers or managers who need to learn more about the typical steps which constitute the preliminary design process in conjunction with the “Bioprocess Facility Design” course which runs on the 24-27th June 2013. Flyers for both can be downloaded here: http://www.ucl.ac.uk/biochemeng/industry/mbi/courses Module Leaders: Daniel Bracewell and Tarit Mukhopadhyay Network: A social networking event will be held for delegates and speakers. Invited Expert Speakers Cost: • • • • Andrew Brown, Biopharm Services Chris Davis, Mott Macdonald Andy Hooker, Syntaxin Ltd Angela Osborne, eXmoor pharma concepts • Vaughan Thomas, Tillingbourne Consulting 0376_2013_UCL_BPM10_proof3.indd 19 The module costs £1300, with a £100 discount if you register and pay before 22 April. 19 14/05/2013 12:37 Contacts Research Sponsors: Dr Karen Smith Director of Bioprocess Leadership +44 (0)20 7679 4411 karen.smith@ucl.ac.uk MBI®: Mrs Liz Cullen MBI® Manager +44 (0)20 7679 1316 mbi-training@ucl.ac.uk EPSRC Centre for Emergent Macromolecular Therapies: Professor Nigel Titchener-Hooker +44 (0)20 7679 3796 nigelth@ucl.ac.uk Industrial Biotechnology and Industrial Doctoral Training Centre (IDTC) for Bioprocess Engineering Leadership: Professor Gary Lye +44 (0)20 7679 7942 g.lye@ucl.ac.uk RegenMed Bioprocessing Professor Chris Mason +44 (0)20 7679 0140 chris.mason@ucl.ac.uk MBI® course dates 2013–14 24–26 June 2013 Industrial Biotechnology and Biorefining 30 Sept–2 Oct 2013 Principles of Fermentation Processes 14–16 Oct 2013 Rapid Fermentation Process Design: From Development to Manufacture 11–14 Nov 2013 Downstream Processing From Cell to Column 25–28 Nov 2013 Downstream Processing: Chromatography 27-29 Jan 2014 Current Challenges in Mammalian Cell Processing 24–27 Feb 2014 tbc Quality by Design for Effective Bioprocess Characterisation and Validation 24–27 Feb 2014 tbc Advanced Cell Therapy Manufacturing Strategies 10–12 March 2014 Design of Experiments for Bioprocess Optimisation 14–16 April 2014 Vaccine Bioprocess Development and Commercialisation 2–5 June 2014 Bioprocess Design & Economic Evaluation 9–11 June 2014 Single Use Technology for Rapid Manufacturing 23–26 June 2014 Bioprocess Facility Design For more information, email mbi-training@ucl.ac.uk Work with us The UCL Advanced Centre for Biochemical Engineering actively encourages and fosters long-term research partnerships between its academics and sponsors for mutual benefit. We facilitate interaction in a range of ways, such as sponsor visits, industrial advisory boards, Bioprocess Briefings, industrial placements for graduate students and the MBI® Programme. Over 70 industrial and academic experts contribute to our MBI® activities. If you would like further information, please contact the appropriate member of staff listed to the left. 20 0376_2013_UCL_BPM10_proof3.indd 20 14/05/2013 12:37